Literature DB >> 12677017

Rapid cerebral ischemic preconditioning in mice deficient in endothelial and neuronal nitric oxide synthases.

Dmitriy N Atochin1, Jeffrey Clark, Ivan T Demchenko, Michael A Moskowitz, Paul L Huang.   

Abstract

BACKGROUND AND
PURPOSE: The purpose of this study was to test the hypothesis that nitric oxide is required for preconditioning in an intact animal model of focal ischemia using neuronal and endothelial nitric oxide synthase (nNOS and eNOS) knockout mice.
METHODS: Cerebral blood flow was measured in wild-type, nNOS knockout, and eNOS knockout mice by hydrogen clearance (absolute) and laser Doppler flowmetry (relative). Mice were preconditioned by three 5-minute episodes of transient middle cerebral artery occlusion (MCAO) and subjected to permanent MCAO. Neurological deficit and infarct size were determined 24 hours later.
RESULTS: Although wild-type mice showed protection from ischemic preconditioning, neither eNOS nor nNOS knockout mice showed protection. Laser Doppler measurements indicated that the relative blood flow decreases in core ischemic areas were the same in all groups.
CONCLUSIONS: Neither eNOS nor nNOS knockout mice show protection from rapid ischemic preconditioning, suggesting that nitric oxide may play a role in the molecular mechanisms of protection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12677017     DOI: 10.1161/01.STR.0000066870.70976.57

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  39 in total

Review 1.  Neuroprotective effects of ischemic preconditioning in brain mitochondria following cerebral ischemia.

Authors:  Miguel A Pérez-Pinzón
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

Review 2.  Ischemic tolerance as an active and intrinsic neuroprotective mechanism.

Authors:  R Anne Stetler; Feng Zhang; Collin Liu; Jun Chen
Journal:  Handb Clin Neurol       Date:  2009

3.  Soluble guanylate cyclase alpha1beta1 limits stroke size and attenuates neurological injury.

Authors:  Dmitriy N Atochin; Izumi Yuzawa; Qian Li; Kristen M Rauwerdink; Rajeev Malhotra; Junlei Chang; Peter Brouckaert; Cenk Ayata; Michael A Moskowitz; Kenneth D Bloch; Paul L Huang; Emmanuel S Buys
Journal:  Stroke       Date:  2010-07-01       Impact factor: 7.914

4.  The Focal-Focal Preconditioning Effect of Photothrombotic Impact on the Signaling Protein Profile in the Penumbra Surrounding the Ischemic Core Induced by Another Photothrombotic Impact.

Authors:  Svetlana V Demyanenko; Anatoly B Uzdensky
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

Review 5.  From rapid to delayed and remote postconditioning: the evolving concept of ischemic postconditioning in brain ischemia.

Authors:  Heng Zhao; Chuancheng Ren; Xingmiao Chen; Jiangang Shen
Journal:  Curr Drug Targets       Date:  2012-02       Impact factor: 3.465

6.  Ubiquilin-1 protects cells from oxidative stress and ischemic stroke caused tissue injury in mice.

Authors:  Yanying Liu; Lanhai Lü; Casey L Hettinger; Gaofeng Dong; Dong Zhang; Khosrow Rezvani; Xuejun Wang; Hongmin Wang
Journal:  J Neurosci       Date:  2014-02-19       Impact factor: 6.167

Review 7.  The role of the ubiquitin proteasome system in ischemia and ischemic tolerance.

Authors:  Robert Meller
Journal:  Neuroscientist       Date:  2009-01-30       Impact factor: 7.519

8.  Preconditioning-induced ischemic tolerance: a window into endogenous gearing for cerebroprotection.

Authors:  Aysan Durukan; Turgut Tatlisumak
Journal:  Exp Transl Stroke Med       Date:  2010-01-21

Review 9.  The neuroprotective mechanism of brain ischemic preconditioning.

Authors:  Xiao-qian Liu; Rui Sheng; Zheng-hong Qin
Journal:  Acta Pharmacol Sin       Date:  2009-07-20       Impact factor: 6.150

10.  Bilateral common carotid artery occlusion as an adequate preconditioning stimulus to induce early ischemic tolerance to focal cerebral ischemia.

Authors:  Lukas Julius Speetzen; Matthias Endres; Alexander Kunz
Journal:  J Vis Exp       Date:  2013-05-09       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.